GSK's ViiV to lean on long-acting HIV portfolio ahead of dolutegravir patent expiration
GSK’s ViiV Healthcare is eyeing 2026 and 2027 for potential longer-acting versions of its respective HIV injectables for prevention and treatment, executives said on a media call Wednesday.
The effort is part of GSK’s plan to bounce back from a key patent expiration in April 2028 for dolutegravir, its blockbuster oral integrase inhibitor. It launched in 2013 as Tivicay and is now a key component of GSK’s two-drug HIV treatments: Dovato and Juluca.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.